ContractUnderwriting Agreement • July 18th, 2019 • Repligen Corp • Biological products, (no disgnostic substances) • New York
Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule I hereto (the “Underwriters”) for whom you are acting as representative (the “Representative”) an aggregate principal amount, as set forth on a term sheet substantially in the form of Schedule III hereto (the “Pricing Term Sheet”), of its 0.375% Convertible Senior Notes due 2024 (the “Firm Securities”). The Company also proposes to sell to the several Underwriters, at the option of the Underwriters, up to an additional principal amount as set forth the Pricing Term Sheet, of its 0.375% Convertible Senior Notes due 2024 (the “Option Securities”). The Firm Securities and the Option Securities are hereinafter referred to collectively as the “Securities”. The Securities will be convertible into cash, shares of common stock of the Company, par value $0.01 per share (the “Common Stock”), or a combination of cash and shares of Common Stock (any shares of Commo
1,380,000 Shares Repligen Corporation UNDERWRITING AGREEMENTUnderwriting Agreement • July 18th, 2019 • Repligen Corp • Biological products, (no disgnostic substances) • New York
Repligen Corporation, a Delaware corporation (the “Company”), proposes to issue and sell to the several underwriters named in Schedule A hereto (the “Underwriters”) an aggregate of 1,380,000 shares of its common stock, par value $0.01 per share (the “Common Stock”). The 1,380,000 shares of Common Stock to be sold by the Company are called the “Firm Shares.” In addition, the Company has granted to the Underwriters an option to purchase up to an additional 207,000 shares of Common Stock as provided in Section 2. The additional 207,000 shares of Common Stock to be sold by the Company pursuant to such option are collectively called the “Optional Shares.” The Firm Shares and, if and to the extent such option is exercised, the Optional Shares are collectively called the “Offered Shares.” J.P. Morgan Securities LLC (“J.P. Morgan”), Stephens Inc. and Janney Montgomery Scott LLC have agreed to act as representatives of the several Underwriters (in such capacity, the “Representatives”) in connec
